Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline

Along with the reverse merger, Candid Therapeutics announced $505 million in private financing to support its pipeline of T cell engagers for autoimmune disease. Lead program cizutamig is on track to begin global Phase 2 testing in myasthenia gravis and interstitial lung disease.

Candid, in a reverse merger with RallyBio, to go public

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Mar 2, 2026-

Rallybio to acquire Candid Therapeutics

US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction.

Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger

Rallybio Corporation (Nasdaq: RLYB) (Rallybio) and Candid Therapeutics, Inc. (Candid), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases, have announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction. In connection with the merger, Candid entered into subscription agreements for a concur…

Candid Therapeutics Announces Merger With Rallybio Corporation, Concurrent Private Financing of $505+ Million // Cooley // Global Law Firm